We are updating our Privacy Policy and Terms and Conditions to help you clearly understand how your personal information is collected, stored and managed. Learn More
Menu Back toBenefit-Risk Management

Benefit-Risk Management

Our best-in-class instructors teach you the Do’s and Don’ts for BRM over the lifecycle of the product, and the course includes the Rev 2 of the GVP Modules V and XVI.


This course is part of the Benefit-Risk and Medical Writing week offering

This intensive course explores current opportunities made possible by the legislation, advances in information technology and new scientific methodology to enhance and modernise the approaches in the product lifecycle management.
The course starts with the current regulatory thinking about the Benefit-Risk methodology, including the relevant projects of the European Medicines Agency (EMA) / Committee for Medicinal Products for Human Use (CHMP). It gives a basis for the second part of the course, exploring the new European Benefit-Risk management planning – a notion stemming from the experience gathered over the past ten years with the EU Risk Management Plans (EU-RMPs). Participants will learn how to take advantage of the efficacy follow-up options given by the EU law and guidelines. A practical training in solving key aspects of the Benefit-Risk management based on real-life examples is included.

Participants will be provided with preparatory material in order to better participate at the group exercises onsite.

What participants from previous courses say:

"Very professional lectors, life-based patterns, high professional attitude from lectors."
Dr. Uldis Armanis, Head of Pharmacovigilance Group, QPPV, JSC Olainfarml

What you will learn

  • Legal possibilities for benefit optimisation and risk minimisation of products in the EU
  • Designing Benefit-Risk management systems using current regulatory tools, including EU Risk Management Plans (EU-RMPs), Development Safety Update Report (DSUR), Periodic Safety Update Report (PSUR)
  • Best study designs for safety and efficacy follow-up, and how to measure their effectiveness

Who should attend?

Professionals most likely to benefit from this training have experience in pharmacovigilance, drug safety, regulatory affairs, quality assurance, risk management, medical affairs or similar positions within the pharmaceutical industry. Those in charge of the design and maintenance of risk management systems, pharmacovigilance auditing or inspecting, Qualified Persons for Pharmacovigilance (QPPVs) and heads of Benefit-Risk management, patient safety, or lifecycle management will learn all the essential aspects needed for successful Benefit-Risk management. Examples are presented for small as well as large organisations.

Learning objectives

At the conclusion of this course, participants will be able to:

  • Describe safety, efficacy, and effectiveness profiles of drugs
  • Plan safety and efficacy follow-up systems, including the best choice of study designs and available registries
  • Optimise benefits and minimise risks of products, including the best use of an evidence-based toolbox
  • Present the Benefit-Risk documents to regulatory authorities and health technology assessment bodies
  • Measure effectiveness of the planned actions – both risk minimisation and benefit optimisation

Participants will complete a knowledge check at the end of the course and will be provided with feedback to ensure learning objectives are attained.

    Plan Your Team's Professional Development

    Why not take advantage and train your whole department (or even across different departments!) and benefit from increased:

    • Focus
    • Flexibility
    • Convenience
    • Cost Effectiveness

    For more information please contact EMEA@DIAglobal.org

    Contact us

    Registration Questions

    Send Email
    +41 61 225 51 51

    Agenda and Logistics

    Send Email
    +41 61 225 51 55